Table 1.
Characteristics of the included studies
| Authors | Year | Country | Study design | AC, (%) | Patient number | M/F | Age (range) | PET parameter | Analysis of PET | PD‐L1 (+), % | Ever‐smoker (%) | Cutoff value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hu et al.22 | 2020 | China | R | 100 | 450 | 203/247 | NR | SUVmax | QA | 9.6 | 74 | 5.5 |
| Hu et al.23 | 2020 | China | R | 82 | 362 | 197/165 | 62.6 (30–87) | SUVmax | QA | 50.8 | 31 | 8.5 |
| Takada et al.24 | 2017 | Japan | R | 83.7 | 256 | NA | 68 (36–89) | SUVmax | QA | 19.4 | 58.9 | 3.2 |
| Takada et al.25 | 2017 | Japan | R | 76.2 | 563 | NA | 69 (36–89) | SUVmax | QA | 23.5 | 61.1 | 4.2 |
| Wu et al.26 | 2019 | China | R | 0 | 24 | 20/4 | 62 (42–79) | SUVmax | QA | 70.8 | 79.2 | 12.4 |
| Zhang et al.27 | 2017 | China | R | 84.9 | 84 | 65/19 | 63 (34–85) | SUVmax | QA | 58.3 | 72.5 | 11.2 |
AC, adenocarcinoma; NA, not available; NR, not reported; QA, quantitative analysis; R, retrospective; SUVmax, maximum standardized uptake value.